Cited by 402Breast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies

The DOI matches its Crossref record.

Endocrine Treatment of Breast Cancer in Women

SANTEN, RICHARD J., MANNI, ANDREA, HARVEY, HAROLD, REDMOND, CAROL·1990·Endocrine Reviews

Open this paper in CoChat — free account

Abstract

Hormonal therapy for breast carcinoma began with the observation by George Beatson (1) in 1898 that bilateral oophorectomy caused tumor regression in selected premenopausal patients. Huggins and Bergenstal (2) later introduced surgical adrenalectomy as a form of hormone ablative treatment for postmenopausal women. To these methods were added surgical hypophysectomy and hormonal additive therapies such as the use of androgens, estrogens, progestins, and glucocorticoids (3). Since only one-third of patients experienced objective tumor regression with any of these hormonal therapies, clinicians began to favor use of cytotoxic chemotherapies in the 1960s and 1970s. During this time multiple chemotherapeutic regimens were developed which gained wide acceptance and enthusiastic support (3). However, when hormone receptor measurements were introduced in the mid-1970s, better selection of patients with hormonally responsive tumors became possible, and new impetus was provided for optimizing hormonal therapies. These developments led to the accumulation of a large body of clinical data regarding hormonal agents and provided clinicians with a broad armamentarium for the treatment of patients at the present time. We will summarize this information with the goals of highlighting specific endocrinological aspects of breast cancer treatment and providing practical perspective for choosing among various agents. Where recent comprehensive reviews are readily available, only pertinent concepts are highlighted.

Integrity signals

Registry

Crossref · 10.1210/edrv-11-2-221

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 301–400 of 402

Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system.
Rékási, Z., Szoke, B. G., Nagy, A., et al. (1993) · Endocrinology · doi:10.1210/endo.132.5.8477650 · Cited by 8
Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients
Freedman, O. C., Amir, E., Dranitsaris, G., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0452-8 · Cited by 8
“The association between age and response to endocrine therapy has been previously reported [25].”
Background and development of aromatase inhibitors
Miller, W. R. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8693-1_1 · Cited by 8
“In terms of the former, aromatase inhibitors reduce endogenously synthesized oestrogens whereas SERMs such as tamoxifen do not inhibit synthesis and oestrogen levels remained unaltered [ 91 ] (or, in the case of premenopausal women, may increase [92, 93]).”
Background
Estrogen antagonism on T3 and growth hormone control of the liver microsomal low-affinity glucocorticoid binding site (LAGS)
López-Guerra, A., Chirino, R., Navarro, D., Fernández‐Pérez, L., Boada, L. D., Zumbado, M. L., & Díaz-Chico, B. N. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00123-4 · Cited by 8
Anti-tumour effect of aromatase inhibitor, CGS16949A, on human breast cancer cells
Yano, S., Tanaka, M., & Nakao, K. (1995) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(95)90097-7 · Cited by 8
METASTATIC BREAST CANCER
Cha, C. H., Kennedy, G. D., & Niederhuber, J. E. (1999) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70064-5 · Cited by 8
Synthetic estrogen-mediated activation of ERK 2 intracellular signaling molecule
Prifti, S., Mall, P., & Rabe, T. (2003) · Gynecological Endocrinology · doi:10.1080/09513590312331290338 · Cited by 8
QSAR Study of Androstenedione Analogs as Aromatase Inhibitors
Oliveira, A. A., Ramalho, T. C., & da Cunha, E. (2009) · Letters in Drug Design & Discovery · doi:10.2174/157018009789353464 · Cited by 8
A New Aromatase Inhibitor, FR901537. I. Taxonomy, Fermentation, Isolation, Physicochemical Characteristics and Biological Activities.
Oohata, N., Hori, Y., Yamagishi, Y., Fujita, T., Takase, S., Yamashita, M., Terano, H., & OKUHARA, M. (1995) · The Journal of Antibiotics · doi:10.7164/antibiotics.48.757 · Cited by 8
Osteoblasts induce osteopontin expression in response to attachment on fibronectin: Demonstration of a common role for integrin receptors in the signal transduction processes of cell attachment and mechanical stimulation
Carvalho, R. S., Schaffer, J. L., & Gerstenfeld, L. C. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19980901)70:3 · Cited by 97
Influence of Antiestrogens on the Invasiveness and Laminin Attachment of Breast Cancer Cells
Rajah, T. T., & Pento, J. T. (1999) · Cancer Investigation · doi:10.1080/07357909909011712 · Cited by 8
The oestrogen paradox: an hypothesis
Santen, R. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1819 · Cited by 7
“Extensive studies demonstrated that only specific subgroups of women respond to high-dose oestrogen [9,12].”
Self-citation
The Female Reproductive System
Jones, R. E. (1991) · Elsevier eBooks · doi:10.1016/b978-0-12-389770-1.50007-x · Cited by 7
Background and development of aromatase inhibitors
Miller, W. R. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7418-7_1 · Cited by 7
A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects
Ahokoski, O., Irjala, K., Huhtala, S., Salminen, E. K., Scheinin, H., & Huupponen, R. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050588 · Cited by 7
“CGS 20267, another aromatase inhibitor, a circadian variation of estrogens was seen, but the study included only three placebo subjects [24].”
Background
Predictive factors for response to endocrine therapy in patients with recurrent Breast Cancer
Sonoo, H., & Kurebayashi, J. (2000) · Breast Cancer · doi:10.1007/bf02966393 · Cited by 7
Male Sex Hormones, Analogs, and Antagonists
Brueggemeier, R. W. (2003) · Wiley eBooks · doi:10.1002/0471266949.bmc055 · Cited by 7
Prognostic and Predictive Factors and Targets for Therapy in Breast Cancer
Klijn, J. G. M., Berns, E. M. J. J., & Foekens, J. A. (2002) · CRC Press eBooks · doi:10.1201/b14039-5 · Cited by 7
Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?
Lønning, P. E. (2000) · Drugs · doi:10.2165/00003495-200060010-00002 · Cited by 6
“Similarly, castration as well as antiestrogens work in premenopausal women; subsequently, followingcastration, thesewomenmay respond to alternative treatment options, such as aromatase inhibition, in the sameway aswomenwho have undergone a natural menopause (see Santen et al.[8] and Lønning and Lien[9] for references…”
Background
Morphological and biological observations relating to the development and progression of breast cancer
Anderson, T. J., & Miller, W. R. (1994) · Cancer treatment and research · doi:10.1007/978-1-4615-2592-9_1 · Cited by 6
Divergent behavior of cyclin E and its low molecular weight isoforms to progesterone-induced growth inhibition in MCF-7 cells
Ghahremani, M., Montazeri, H., Bouzari, S., et al. (2014) · Advanced Biomedical Research · doi:10.4103/2277-9175.148299 · Cited by 5
“[7,8] The course of action for the antitumor activity of progestins is yet to be identified but restraint of cell cycle within G 1 phase indicates that these compounds act by affecting expression of the genes involved in progression of cell cycle through G 1 .”
Hormonal therapy of breast cancer
Lebowitz, P. F., & Zujewski, J. A. (2003) · Current Problems in Cancer · doi:10.1016/s0147-0272(03)00049-7 · Cited by 5
Aromatase inhibitors in the treatment of male infertility
Elkhiat, Y., & Fahmy, I. (2011) · Human Andrology · doi:10.1097/01.xha.0000397087.63955.45 · Cited by 5
AROMATASE INHIBITORS - TYPES AND ADVANTAGES
Paul, C., & Sudandiradoss, C. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 5
A New Aromatase Inhibitor, FR901537. II. Pharmacological and Antitumor Effects.
Oohata, N., Kawamura, I., LACEY, E., et al. (1995) · The Journal of Antibiotics · doi:10.7164/antibiotics.48.763 · Cited by 5
Exemestane and Chemotherapy as First-line Treatment of Metastatic Breast Cancer: Results of a Phase II Study
de la Haba-Rodríguez, J., Mancha, R. G., Manga, G. P., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.041 · Cited by 4
Facile Synthesis of Novel Ti2C Nano Bipyramids for Photothermal and Photodynamic Therapy of Breast Cancer
Ali, I., Chang, L., Farheen, J., et al. (2024) · ChemPlusChem · doi:10.1002/cplu.202300544 · Cited by 4
Tratamento endócrino dos meningiomas: uma revisão
da Motta, L. A. C. R., & da Motta, L. D. C. (1995) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x1995000200027 · Cited by 4
Effect of Epilobium angustifolium and Serenoa repens extracts on regulation of non-genomic signaling pathway of kinases
Kujawski, R., Bogacz, A., Bartkowiak-Wieczorek, J., et al. (2014) · Ginekologia Polska · doi:10.17772/gp/1723 · Cited by 4
Medical Therapies: Aromatase Inhibitors
Bulun, S. E., Attar, E., Gürateş, B., Chen, Y., Tokunaga, H., Monsivais, D., & Pavone, M. E. (2011) · Wiley eBooks · doi:10.1002/9781444398519.ch35 · Cited by 4
Effect of Decapeptyl® (a GnRH analogue) and of transforming growth factor-α (TGF-α), in the presence of heparin, on the sulfatase activity of human breast cancer cells
Chetrite, G. S., Blumberg-Tick, J., & Pasqualini, J. R. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00004-j · Cited by 4
Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art
Paraiso, P., van Deurzen, C. H. M., & Seimbille, Y. (2026) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-026-00446-y · Cited by 4
“Besides, PR status may correlate more strongly to endocrine response than ER status alone (Lanari et al. 2009; Horwitz et al. 1978; Natrajan et al. 2010; Horwitz and McGuire 1975; Hammond et al. 2010; Santen et al. 1990; Bardou et al. 2003; Osborne and Tripathy 2005).”
Stroma-mediated expression of estrogen and its role in cancer.
Sachdeva, M., & Mo, Y. (2010) · Frontiers in Bioscience · doi:10.2741/3618 · Cited by 6
Catalytic Hydrogenation of Halosteroidal Derivatives by Bipyridine or Phenanthroline Complexes of Copper(II) in Hydrazine Aqueous Media
Du, H., Liu, K., & Li, W. (2006) · Synthetic Communications · doi:10.1080/00397910500408522 · Cited by 3
“1–4 Recently, new types of steroidal estrogen‐based antagonists were developed because of the side effects of the partial estrogenic activity of Tamoxifen, 5 the most widely used drug in breast cancer patients for more than 30 years.”
Background
GnRH and steroids in cancer
Florio, S. (2002) · Frontiers in bioscience · doi:10.2741/florio · Cited by 3
GnRH and steroids in cancer
Florio, S. (2002) · Frontiers in bioscience · doi:10.2741/a864 · Cited by 3
Microarray expression profiling of long noncoding RNAs in the progesterone‐treated lung cancer cells
Xie, M., Lu, X., & Chen, Q. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3215 · Cited by 3
“Progestin and its derivatives are currently used as a protective therapy to counteract the pro-proliferative effects of estrogen in breast cancer and endometrial carcinoma patients.(6) Similarly, progestogens are prescribed for post-menopausal women on estrogen hormone replacement therapy to protect them from the incr…”
Background
Nuclear oncogenes in breast cancer
Dubik, D., Watson, P. H., Venditti, M., et al. (1996) · Cancer treatment and research · doi:10.1007/978-1-4613-1259-8_9 · Cited by 3
Clinical Aspects of Breast Cancer
Gradishar, W. J., & Morrow, M. (1996) · Hormones and Cancer · doi:10.1007/978-1-4612-4266-6_6 · Cited by 3
Vitamin D and Breast Cancer
van Leeuwen, J. P. T. M., Wijngaarden, T. V.-V., & Pols, H. A. P. (1999) · Humana Press eBooks · doi:10.1007/978-1-4757-2861-3_24 · Cited by 3
Pharmacologic Manipulation of Steroid Hormones: Adjunctive Therapies in Cancer of the Breast
Manni, A. (1991) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30246-9 · Cited by 3
Self-citation
The duration of adjuvant tamoxifen therapy
Bilimoria, M. M., & Jordan, V. C. (1998) · Cancer treatment and research · doi:10.1007/978-1-4615-6189-7_10 · Cited by 3
Anthracycline-resistant breast cancer
Hortobágyi, G. N., Pivot, X. B., & Asmar, L. (1997) · Breast Cancer · doi:10.1007/bf02966510 · Cited by 2
Hormone Responsive Cancers
Santen, R. J., Duska, L., & Culp, S. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00029-9 · Cited by 2
Self-citation
Effect of Estrogen and Antiestrogen Therapy in Rats Bearing Mesenchymal Tumors
Remedi, M. M., Demarchi, M., Hliba, E., et al. (1999) · Tumor Biology · doi:10.1159/000030070 · Cited by 2
The evolving role of endocrine therapy for early stage breast cancer
Manders, J. B., & Gradishar, W. J. (2005) · Breast Cancer · doi:10.2325/jbcs.12.62 · Cited by 2
The Synthesis of Novel aza-Steroids and α, β-Unsaturated-Cyanoketone from Diosgenin
Mesa, D., Augusto, Y. E., Hernández, G., Figueroa-Macías, J. P., Coll, F., Olea, A. F., Núñez, M., Campo, H. A., Coll, Y., & Espinoza, L. (2023) · Molecules · doi:10.3390/molecules28217283 · Cited by 1
Progesterone and progesterone receptors in breast cancer: past, present, and future
Rodionova, M. V., Родионов, В. В., Кометова, В. В., et al. (2024) · Tumors of female reproductive system · doi:10.17650/1994-4098-2024-20-4-70-80 · Cited by 1
PPARy - predstavitel' semeystva yadernykh steroidnykh retseptorov
Кононенко, И. В., & Smirnova, O. M. (2005) · Diabetes Mellitus · doi:10.14341/2072-0351-5785 · Cited by 1
Historia de los receptores hormonales y de la terapia hormonal en cáncer de mama
Guerra, L. M. B., Rodríguez-Orihuela, D. L., Soto‐Pérez‐de‐Celis, E., & Chávarri-Guerra, Y. (2021) · Medicina · doi:10.56050/01205498.1594 · Cited by 1
Ovarian Stimulation
(2022) · Cambridge University Press eBooks · doi:10.1017/9781316477021 · Cited by 1
The breast: lactation and breast cancer as an endocrine disease
Santen, R. J. (2011) · doi:10.1093/med/9780199235292.003.0928 · Cited by 1
Self-citation
Induction of Ovulation
Martinez, A. M., & Lindheim, S. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6837-0_14 · Cited by 1
Breast Cancer
Santen, R. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4907-4.00027-9 · Cited by 1
Self-citation
Effects of chemotherapy-induced ovarian failure on bone and lipid metabolism in premenopausal breast cancer patients : Impact of adjuvant clodronate and tamoxifen
Vehmanen, L. (2005) · Työväentutkimus Vuosikirja · Cited by 1
The Oestrogen-Regulated pS2-BCEI Protein in Breast Cancer
Milgröm, E. (1992) · Springer eBooks · doi:10.1007/978-3-642-77662-5_3 · Cited by 1
Effects of the aromatase inhibitor fadrozole on gene expression in the zebrafish brain
Paquette, M. (2009) · uO Research (University of Ottawa) · doi:10.20381/ruor-19103 · Cited by 1
“Inhibiting aromatase activity has been shown to be an effective technique to reduce estrogens in post-menopausal women who have estrogen-dependent advanced breast cancer (Santen et al., 1990).”
Method
The role of hormonal therapy in breast cancer
Noguchi, M., & Miwa, K. (1998) · Breast Cancer · doi:10.1007/bf02967413 · Cited by 1
Immunohistochemical Detection of Aromatase in Breast Carcinomas
Tsunoda, Y., KAMIYA, K., Tsunoda, A., Sawada, T., Kusano, M., Shimizu, Y., Yanaihara, T., Takimoto, M., & Ohta, H. (2000) · The Showa University Journal of Medical Sciences · doi:10.15369/sujms1989.12.247 · Cited by 1
Use of endocrine therapy to study the biology of breast cancer
Lønning, P. E. (1993) · Cancer Treatment Reviews · doi:10.1016/0305-7372(93)90008-f · Cited by 1
Hormones, Sex Hormones
Gunnet, J. W., & Dixon, L. A. (2000) · Kirk-Othmer Encyclopedia of Chemical Technology · doi:10.1002/0471238961.19052407211414.a01 · Cited by 2
Malignancies of the Ovaries
Vahrson, H., Nitz, U. A., & Bender, H. (1997) · Medical radiology · doi:10.1007/978-3-642-60334-1_11 · Cited by 1
The Endocrine Society Centennial: 40 Years of Aromatase Inhibitors as Targeted Therapy for Breast Cancer
Lee, A. V. (2016) · Endocrinology · doi:10.1210/en.2016-1623 · Cited by 1
Palliative systemic antineoplastic therapy
Patel, S. M., & Fisch, M. J. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511642357.022
Organ-Selective Actions of Tamoxifen and Other Partial Antiestrogens
Turner, R. T. (1995) · Springer eBooks · doi:10.1007/978-3-662-09153-1_4
Systemic Treatment Approaches in Breast Cancer
Bontenbal, M. (1997) · RePub (Erasmus University Rotterdam)
Mild forms of ovarian stimulation
Aboulghar, M. A., & Rizk, B. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511762390.004
An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
Gutteridge, E. (2010) · Nottingham ePrints (University of Nottingham)
Facilitated Binding of Steroid Hormone Receptors to Target DNA by the Chromatin High-Mobility Group Protein-1: Protein Manipulation of DNA Structure
Edwards, D. P., & Prendergast, P. (1997) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4612-2004-6_8
Estrogen-Receptor and Antiestrogen-Receptor Complexes: Cell- and Promoter-Specific Effects and Interactions with Second Messenger Signaling Pathways
Katzenellenbogen, B. S., Montano, M. M., Kraus, W. L., et al. (1995) · Springer eBooks · doi:10.1007/978-3-662-09153-1_2
“Although antiestrogens bind to the ER in a manner that is competitive with estrogen, they fail to effectively activate gene transcription (Jordan and Murphy 1990; Katzenellenbogen et al. 1985; Santen et al. 1990).”
Background
Is there a place for progestin agents in breast cancer prevention?
Gompel, A., Lévy, D., Chaouat, M., et al. (2002) · International Congress Series · doi:10.1016/s0531-5131(01)00467-8
Compared to tamoxifen, letrozole increases tumor response in post-menopausal women with advanced breast cancer
Sivasubramaniam, V., & Lyman, G. H. (2002) · Evidence-based Oncology · doi:10.1054/ebon.2001.0183
Solving the puzzle of hormone-dependent breast cancer.
Santen, R. J. (1992) · PubMed
Self-citation
The Mode of Therapeutic Action of Metformin and Aromatase Enzyme Inhibitors in the Treatment of Induced Polycystic Ovary Syndrome in Rat through using Immunohistochemical Technique
Al-Waeli, A. M., & Al-Khalisy, M. H. (2015) · Advances in life science and technology
Insight into estrogen action in breast cancer via the study of a novel nuclear receptor corepressor: SLIRP
Hatchell, E. C. (2008) · UWA Profiles and Research Repository (UWA)
Superior E fficacy o f L etrozole V ersus T amoxifen a s First-Line T herapy f or P ostmenopausal W omen W ith Advanced B reast C ancer: R esults o f a P hase I II S tudy o f the I nternational L etrozole B reast C ancer G roup
Mouridsen, H. T., Gershanovich, M., Sun, Y., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R. E., Sleeboom, H. P., Pluzanska, A., Dank, M., et al. (2001)
A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SINGLE AND COMBINATION THERAPIES OF LETROZOLE AND GONADOTROPINS IN OVULATION INDUCTION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
Cherian, A. M., Rajiah, K., Dharamsi, A. T., & Kumar, V. (2012)
Clinical Utility of Aromatase Inhibitors
Shenton, K., Dowsett, M., & Dukes, M. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-152-7_12
Investigating the effects of exercise on initiation of nitrosomethylurea induced mammary tumorigenesis in young rats
Whittal, K. S. (1996) · Summit (Simon Fraser University)
DEVELOPMENT OF NANOSCALE BIOSENSORS FOR CANCER RELATED PROTEASES AND BLOOD-BORNE PATHOGENS BASED ON ELECTROCHEMICAL AND OPTICAL METHODS by
Swisher, L. Z. (2015) · K-State Research Exchange (Kansas State University)
Regulación de la proliferación y diferenciación de células de endometrio por hormonas esteroideas ováricas
Citrinovitz, M., & Cecilia, A. (2014)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Secretariat, A. (2002)
Preclinical pharmacology of bombesin antagonists
Radulovic, S. S. (1993) · doi:10.2298/bg19931203radulovic
Investigation of the mechanisms of estrogen receptor activation by phosphorylation
Halliday, A. C. (2009) · Spiral (Imperial College London) · doi:10.25560/4348
“Reduction of estrogen levels by surgical oophorectomy in pre-menopausal women with hormone-dependent breast cancers causes tumour regression, however, after 12-18 months tumours begin to re-grow even in the reduced estrogen environment (Santen et al., 1990).”
Background
Time to Update Environmental Regulations Should public health standards for endocrine-disrupting compounds be based upon sixteenth century dogma or modern endocrinology?
Myers, J. P. (2008)
The microenvironment in health and cancer of the mammary gland
Wiebe, J. P. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511973642.004
Differential Effects Of Estradiol And Tamoxifen On Pyrrolidon Carboxypeptidase Activity In The Human Estrogen-dependent And Estrogen-independent Breast Cancer Cell Lines MCF-7 And EVSA-T
Martı́nez-Martos, J. M., Carrera-González, M. P., Mayas, M. D., et al. (2010)
Combined T amoxifen a nd L uteinizing H ormone-Releasin g Hormone ( LHRH) A gonist V ersus L HRH A gonist A lone i n Premenopausal A dvanced B reast C ancer: A M eta-Analysis of F our R andomized T rials
Boccardo, F., Tominaga, T., Duchateau, L., et al. (2001)
New Diagnostic Methods and Treatment Modalities in Breast Cancer
Klijn, J. G. M., Berns, P. M. J. J., Bontenbal, M., et al. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3494-5_22
Tactics for minimizing risk of increasing estradiol against the background of aromatase inhibitors in combination with gonadotropin releasing hormone agonists in adjuvant therapy for breast cancer in premenopausal patients. Pilot study results
Кононенко, И. Б., Снеговой, А. В., Manzyuk, L. V., Kovalenko, E. I., & Selchuk, V. Y. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-19-76-84
New Endocrine Agents for Breast Cancer
Manni, A. (1992) · Springer eBooks · doi:10.1007/978-3-642-77662-5_7
Self-citation
Oral Agents for Ovarian Stimulation
Mitwally, M. F., & Casper, R. F. (2022) · Cambridge University Press eBooks · doi:10.1017/9781316477021.004
Expresión de los ARNm que codifican para las enzimas que biotransforman a la testosterona en células humanas de carcinoma mamario
Núñez, L. G. (2007) · doi:10.24275/uami.vm40xr826
Docking simulations of steroidal oximes toward Estrogen Receptor alpha. Analysis of their potential anticancer activity
Alonso, D., Mesa, D., Hernández, G., Olea, A. F., Espinoza, L., & Coll, Y. (2023) · Journal of the Chilean Chemical Society · doi:10.4067/s0717-97072023000305918
10.1016/b978-1-4160-2911-3.50044-3
(2000) · Time to knit · doi:10.1016/b978-1-4160-2911-3.50044-3
The Development and Current Role of Oral Fertility Medications Such as Clomiphene Citrate and Aromatase Inhibitors in IVF
Mitwally, M., & Casper, R. F. (2025) · Springer eBooks · doi:10.1007/978-3-031-77255-9_3
Twenty-five Years of Endocrine Oncology with Analogs of Hypothalamic Peptides: An Overview
Schally, A. V. (2003) · Springer eBooks · doi:10.1007/978-88-470-2085-6_1
Rôle des chimiokines dans les interactions entre les cellules stromales mésenchymateuses et les cellules de cancer du sein
Escobar, P. A. (2010) · theses.fr (ABES) · doi:10.70675/6ef77dc7ze8f2z4d7bza761zc1f42658f0a5
Design, synthesis and biological effects studies of new imidazole-oxadiazole derivative compounds
Osmani̇ye, D., Ali, S. J. H., Çelikateş, B. K., Sağlık, B. N., Levent, S., Özkay, Y., & Kaplancıklı, Z. A. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146999
Construction and application of mammary and breast cancer organoids
Meng, Y., Bai, P., Zhang, L., Zhang, M., & Cai, C. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100354
“…can lead to various breast diseases, including breast cancer (Yu et al., 2016; Zhang et al., 2022), mastitis (Amir et al., 2007; Kvist et al., 2008; Santen et al., 1990), breast fibrosis (Boyd et al., 2007; Guray & Sahin, 2006), and fibroade-nomas (El-Wakeel & Umpleby, 2003; Guray & Sahin, 2006),…”

Authors: SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C.
Affiliations: Pennsylvania State University (US)
Corresponding author: SANTEN, RICHARD J.
ORCID: SANTEN, RICHARD J.
Venue: Endocrine Reviews
Publisher: The Endocrine Society
Published: 1990-05
Volume: 11
Issue: 2
Pages: 221-265
ISSN: 0163-769X (ISSN-L)
1945-7189
DOI: 10.1210/edrv-11-2-221
OpenAlex: W2114712559
Cited by: 399
References: 0
Citations by year: 2026: 3 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 5 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 5 · 2013: 11 · 2012: 4
FWCI: 11.36
Type: journal article
Language: en
Open access: closed
Locations: Endocrine Reviews (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: breast cancer, endocrine therapy, hormone therapy, oophorectomy, adrenalectomy, hypophysectomy, androgens, estrogen, progestins, glucocorticoids, tumor regression, treatment selection
MeSH terms: Androgens, Breast Neoplasms, Estrogen Antagonists, Estrogens, Female, Glucocorticoids, Humans, Progestins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Endocrine Treatment of Breast Cancer in Women

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks